APP

(redirected from beta-amyloid peptide)
Also found in: Dictionary, Medical, Encyclopedia.

Application

1. A formal request. Generally, one must fill out an application form as part of the application process.

2. See: Application Program.

APP

Shorthand for appreciation.
References in periodicals archive ?
A collaborative team of researchers from Columbia University, Stanford University, and the Gladstone Institute of Neurological Disease in San Francisco demonstrated that astrocytes isolated from adult mouse brains can degrade and remove beta-amyloid peptides (Wyss-Coray et al.
Filaments of tau protein accumulate inside these cells, and plaques of beta-amyloid peptide collect outside the cells.
The study's findings showed how the mechanism of action of GAMMAGARD may work on multiple forms of the beta-amyloid peptide to protect the human brain from dementia and may facilitate the development of treatment for patients with Alzheimer's disease.
SP233 was shown to bind to beta-amyloid peptide, prevent its oligomerization and entry into neurons, protect neuronal mitochondria from beta-amyloid-induced damage, and maintain neuronal cell energy levels.
Over 30 R&D projects directed against beta-amyloid peptides are now in various stages of development in the industry but the potential for this approach to yield clinical benefit remains unproven.
While that compound is no longer in development, Elan and Wyeth have initiated a Phase I trial studying a new monoclonal antibody specifically designed and engineered to clear the neurotoxin beta-amyloid peptide that accumulates in the brains of patients with Alzheimer's disease.
A family of molecular pumps found in cells throughout the body, ABC transporter substrates and associated diseases rank among the key prizes in the pharmaceutical industry: the beta-amyloid peptide which aggregates in the brain to cause Alzheimer's disease, all-trans retinal whose inefficient removal from the retina causes macular degeneration, and cholesterol which deposits in the vasculature to cause atherosclerosis.
Reiner, President & CEO stated, "Recent advances in understanding the role of the beta-amyloid peptide in Alzheimer's disease strongly validate the direction we took several years ago.
Researchers at Elan Corporation, plc (NYSE: ELN) ("Elan") reported today in the scientific journal, Nature, that immunization with a 42 amino acid form of the beta-amyloid peptide (AB42), called AN-1792, significantly reduced pre-existing amyloid plaque and inhibited further plaque formation in the brains of Elan's transgenic (PDAPP) mouse model of Alzheimer's disease.
Athena and its collaborators recently completed a clinical research study that tested levels of tau and a form of the beta-amyloid peptide in the cerebral spinal fluid of 120 AD patients and relevant controls.